Truesdale Medical Center Opens in North Charleston, Offering HIV Care and Primary Medical Care

Read More

NORTH CHARLESTON, S.C. – ?Truesdale Medical Center, offering both primary medical care and treatment specific to those living with HIV, has opened in North Charleston. The center operates in partnership with Palmetto Community Care, a nonprofit providing complete compassionate HIV care and prevention education awareness in the Charleston area.

Truesdale Medical Center is located at 6296 Rivers Ave., Suite 310 in North Charleston, in the Trident United Way building. It provides a variety of services, including HIV medical care, HIV primary care, primary care for non-HIV patients, treatment for acute illness and chronic illness as well as gynecological services, viral hepatitis management and prevention and treatment for other sexually transmitted infections.

“Truesdale Medical Center is committed to providing excellence in health care as well as focusing on complete, compassionate HIV care and preventative medical services,” said Bradley Childs, CEO of Truesdale Medical Center and Executive Director of Palmetto Community Care. “This is a much-needed resource for the community and for HIV-positive clients at Palmetto Community Care.”

While clients at Palmetto Community Care will be able to receive both HIV care and primary care services at Truesdale Medical, members of the community ages 16 and up can seek care at the center as well. The general public can pay for services with insurance, Medicaid and Medicare.

Jami Dybik is the center’s practice manager. She previously was financial services coordinator for Palmetto Community Care. Samantha Wadford is the family nurse practitioner. She has 18 years of experience working in community and hospital nursing, most recently as the family planning nurse consultant for S.C. Department of Health and Environmental Control.

The center’s physician is William D. Largen, MD, a graduate of Temple University School of Medicine. He completed his residency in internal medicine and fellowship in infectious disease at the Medical University of South Carolina. He has a strong passion for managing the complexities of HIV care, including the special psycho-social support it requires.

“With more than 500 HIV-positive clients at Palmetto Community Care, we know that our community needed another medical provider for HIV primary care. Our central location at the epicenter of the HIV epidemic in the Lowcountry combined with 27 years of work in the HIV/AIDS community ensures that we are very well equipped to help all HIV-positive patients with a full spectrum of medical care, and focus on those most at need for complete, compassionate medical care and preventative services,” Childs said.

Truesdale Medical Center is named in memory of James Edward “Jimmy” Truesdale who passed away on Feb. 12, 2017, at the age of 76. Truesdale was a dedicated supporter of Lowcountry AIDS Services (now Palmetto Community Care) for many years, including serving as president of the board of directors.

Truesdale Medical Center is open 8 a.m. to 4 p.m. Monday, Tuesday, Thursday; 9 a.m. to 6 p.m. on Wednesday; and from 8 a.m. to noon on Friday. To schedule an appointment, call 843-266-3870. Learn more about Truesdale Medical Center at www.truesdalemedical.org.

###

About Truesdale Medical Center
Founded in 2018, Truesdale Medical Center’s mission is to improve the health of those it serves through excellence in patient care and the utilization of evidence-based practices. Truesdale Medical Center, located in North Charleston, focuses on providing excellent health care to its clients with a focus on complete, compassionate HIV Care and prevention. Learn more at www.truesdalemedical.org or at www.facebook.com/TruesdaleMedical.

Corindus Vascular Robotics, Inc. Names MUSC Practicing Physician Aquilla S. Turk, D.O. as Chief Medical Officer, Neuroendovascular

Read More

Steering Committee of 8 Neurovascular Physicians Developed to Advance Robotic Technology for Neurovascular Interventions and Acute Stroke Care

WALTHAM, Mass.–(BUSINESS WIRE)– Corindus Vascular Robotics, Inc. (NYSE American:CVRS), a leading developer of precision vascular robotics, announced today that Aquilla “Quill” Turk, D.O. has joined the company as Chief Medical Officer, Neuroendovascular. Dr. Turk is a practicing physician at the Medical University of South Carolina where he serves as Director of the Stroke and Cerebrovascular Program, Director of the Neuroendovascular Program, and Professor with a joint appointment in the Departments of Radiology and Neurosurgery. Dr. Turk will serve alongside Dr. Aaron Grantham, Corindus’ Cardiovascular CMO, to spearhead the company’s clinical initiatives and expand robotic treatment into neurovascular procedures, specifically targeting acute ischemic stroke.

“I am pleased to welcome Dr. Turk to the Corindus team. His guidance and expertise will be critical as we expand our focus and technology to include treatment for neurovascular interventions,” stated Mark Toland, President and Chief Executive Officer of Corindus. “We strongly believe that our technology pipeline can add value across the spectrum of vascular interventions, with remote access and advanced robotic capabilities at the forefront of our strategy.”

In addition to Dr. Turk’s appointment, Corindus has established a Physician Steering Committee dedicated to Neuroendovascular Procedures, which will be led by Dr. Turk. Members include:

  • Ricardo A. Hanel, M.D., Ph.D., Baptist Health System, Jacksonville, FL
  • Tudor G. Jovin, M.D., University of Pittsburgh Medical Center, Pittsburgh, PA
  • J. Mocco, M.D., The Mount Sinai Hospital, New York, NY
  • Raul G. Nogueira, M.D., Grady Memorial Hospital, Atlanta, GA
  • Vitor Mendes Pereira, M.D., MSc, Toronto Western Hospital-University Health Network, Toronto, ON
  • Adnan Siddiqui, M.D., Toshiba Stroke & Vascular Research Center, UB, Buffalo, NY
  • Satoshi Tateshima, M.D., Ronald Reagan UCLA Medical Center, Santa Monica, CA
  • Raymond D. Turner, M.D., Medical University of South Carolina, Charleston, SC

“I look forward to partnering with the Corindus team and the company’s Neuroendovascular Steering Committee to bring robotic treatment to neurovascular care,” said Dr. Turk. “I believe that robotics will be critical to transforming the treatment paradigm for the neurovascular space. Speeding up treatment time through remote access capabilities and robotic precision will revolutionize how patients with illnesses such as acute stroke receive treatment.”

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company’s CorPath? System is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and percutaneous vascular procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. CorPath GRX is the second generation robotic-assisted PCI technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit “One Stent Program.” For additional information, visit www.corindus.com, and follow @CorindusInc.

Forward-Looking Statements

Statements made in this release that are not statements of historical or current facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus’ control.

Examples of such statements include statements regarding or such as:

  • CMO Turk will spearhead Corindus’ clinical initiatives to expand robotic treatment into neurovascular procedure, specifically targeting acute ischemic stroke;
  • Corindus’ strong belief that its technology pipeline can add value across the spectrum of vascular interventions, with remote access and advanced robotic capabilities at the forefront of its strategy; and
  • the belief that robotics will be critical to transforming the treatment paradigm for the neurovascular space and that speeding up treatment time through remote access capabilities and robotic precision will revolutionize how patients with illnesses such as acute stroke receive treatment.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, including, but not limited to the following: the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date. More information is available on Corindus’ website at http://www.corindus.com .

Corindus Vascular Robotics, Inc.
Media:
Kate Stanton, 508-653-3335 ext. 200
kate.stanton@corindus.com
or
Investor Relations:
Lynn Pieper Lewis, 415-937-5402
ir@corindus.com

Source: Corindus Vascular Robotics, Inc

Silent but Deadly: A Personal Charleston Opioid Addiction Story

Read More

By Mackenzie Miller

It has crept upon us, and it’s hard to tell who it comes from. No. It’s not what you think. I am referring to the gradual prevalence of opioid addiction that has traversed our nation. With its rising death toll, it has been declared a national epidemic. Dare I say the “T” word. My addiction crept up over the course of eight months after a knee surgery. At first, my doctor prescribed me bottles of Oxycodone (Oxy) for my physical pain. After a while, that pain diminished. What was left was an emotional pain. An emptiness created by my isolation that needed to be suppressed. Oxy was my solution. My doctor kept prescribing it to me as long as I appeared to be in physical pain.

I tried to convince myself that I could stop whenever I wanted. I told myself I would stop once my knee was back to normal, whatever that meant. But deep down, I knew that was a lie. It wasn’t until my addiction starting affecting my job that I noticed my cavalier habit was a sincere problem. The job is usually what goes first. It’s gone after one blink. Plus, the week-long stint in the hospital was an eye opener.

One lesson I learned from this enlightening experience, aside from the obvious, is to choose your friends wisely. I am lucky to have a great group of friends. These loyal friends of mine sprinted into action once they were aware of my problem. I hid it well. When you have friends here and there that don’t all know each other, it makes it easy to slowly withdraw from them. But it didn’t take them long to put the pieces together, noticing all the red flags along the way.

Choose your friends wisely. The ones who will buy tampons for you in the middle of the night. The ones who will drive you to the airport at four in the morning. Keep those around. They are the ones who will be visiting you in the hospital while you are hooked up to two IVs and pissing in a bed pan.

*The name has been changed to protect the privacy of the author

We would like to thank the author for her courage in sharing this story with us.

MUSC named one of the first national telehealth centers of excellence with HRSA grant

Read More

CHARLESTON, S.C., Oct. 3, 2017 /PRNewswire-USNewswire/ —?The Medical University of South Carolina (MUSC) has been awarded a $600,000 grant from the Health Resources and Services Administration (HRSA), an agency of the U.S. Department of Health and Human Services. The award marks MUSC as one of only two national Telehealth Centers of Excellence in the United States. As a national telehealth coordinating center, MUSC will continue to provide a range of telehealth services at more than 200 locations statewide, leading and modeling the way for health care delivery through advanced technology.

“This is a phenomenal achievement,” said Patrick J. Cawley, M.D., MUSC Health CEO and vice president for Health Affairs. “This grant acknowledges the premier position that our telehealth team has established not only in South Carolina, but across the nation. It serves as another clear affirmation of our institution’s commitment to fulfill our vision – to lead health innovation for the lives we touch.”

As a founding member of the South Carolina Telehealth Alliance (SCTA), a collaboration to empower care providers and patients across the state to effectively use telehealth, MUSC is uniquely qualified to lead these efforts. The institution has a long history of executing its three-part mission in a state with largely rural areas and high rates of chronic disease among a particularly impoverished and medically underserved population. Familiar with the patient care, research, and educational leadership talent within the institution, the South Carolina legislature has generously supported expanding telehealth across the state through the SCTA, acknowledging MUSC’s proven track record of achieving astronomical growth in telehealth services while keeping cost effectiveness at the forefront.

“This is one of the first of its kind HRSA grants with only two awarded in the entire country,” said Shawn Valenta, MUSC Center of Telehealth director. “Grant funds will allow the MUSC telehealth team to leverage the unique qualities intrinsic to our academic medical center and extend this mission nationally to accelerate the dissemination of best practices to achieve effective and efficient care.”

Through the grant, MUSC will continue to:

  • Look beyond using telehealth to merely replicate care over distance.
  • Achieve efficiencies within health care delivery and assess the impact on the patient, the referring site, the consulting provider, the payer, and the health care system.
  • Balance the need for population-level outreach while concurrently using a targeted approach to health system integration.
  • Foster a culture of collaboration and understand the importance of interdisciplinary efforts.
  • Strive for deep understanding of barriers and facilitators for the diffusion of innovations in rural health care settings and team experience in overcoming these barriers.
  • Enhance alignment of historically competing health systems for the benefit of patients.
  • Reinforce the commitment and expertise necessary to use evidence-based, data-driven approaches to identify needs for telehealth services, and to monitor and improve existing programs.
  • Work with legislators and policy-makers to develop and maintain bipartisan support for telehealth initiatives.
  • Demonstrate robust financial accountability and efficient use of resources for telehealth.
  • Rely on proven ability to recognize and facilitate the development and testing of new ideas for improving rural health and the care of underserved populations.
  • Build upon high levels of provider acceptance through innovative education and training initiatives.

“The South Carolina legislature has placed a lot of trust in MUSC and the other members of the South Carolina Telehealth Alliance to use telehealth to improve access to quality health care in our state,” said South Carolina Representative G. Murrell Smith. “This achievement is a testament to the leadership, collaboration and hard work that’s been taking place these last few years. We are proud of what MUSC and SCTA have been able to accomplish thus far, and we take comfort knowing that no matter what happens with the health care debate at the national level, we have an effective and cost-conscious model that we hope one day will enable every citizen of our state to access the high-quality care they deserve.”

Smith’s colleague at the statehouse, South Carolina Senator Thomas C. Alexander, echoed the praise for MUSC and SCTA. “Innovation in health care is a critical component of how we offer forward-thinking solutions to today’s challenges,” he said. “The South Carolina legislature recognized the potential for MUSC and SCTA to carve the path to better health across this state by employing advanced technology and strategic thinking. This grant gives MUSC the opportunity to share that knowledge and success on a national level, and we are proud to support this extended impact.”

About MUSC
Founded in 1824 in Charleston, The Medical University of South Carolina is the oldest medical school in the South. Today, MUSC continues the tradition of excellence in education, research, and patient care. MUSC educates and trains more than 3,000 students and 700 residents in six colleges (Dental Medicine, Graduate Studies, Health Professions, Medicine, Nursing, and Pharmacy), and has nearly 13,000 employees, including approximately 1,500 faculty members. As the largest non-federal employer in Charleston, the university and its affiliates have collective annual budgets in excess of $2.3 billion, with an annual economic impact of more than $3.8 billion and annual research funding in excess of $250 million. MUSC operates a 700-bed medical center, which includes a nationally recognized children’s hospital, the Ashley River Tower (cardiovascular, digestive disease, and surgical oncology), Hollings Cancer Center (a National Cancer Institute-designated center), Level I trauma center, Institute of Psychiatry, and the state’s only transplant center. In 2017, for the third consecutive year, U.S. News & World Report named MUSC Health the number one hospital in South Carolina. For more information on academic programs or clinical services, visit musc.edu. For more information on hospital patient services, visit muschealth.org.

CONTACT:? Heather Woolwine
843-792-7669
woolwinh@musc.edu?